Retatrutide

Fat LossInvestigational

Overview

Retatrutide (LY3437943) is a triple agonist peptide targeting GIP, GLP-1, and glucagon receptors. Developed by Eli Lilly, it represents the next generation of incretin-based therapies. Phase 2 clinical trials have shown unprecedented weight loss results, and Phase 3 trials are ongoing.

Evidence Strength

🟡

Limited Human Evidence

Preliminary or limited human data available

🟢Human Clinical Evidence

🟡Limited Human Evidence

🟠Mostly Animal Research

🔴Preclinical / Laboratory

This information is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making any health decisions.